THE ROLE OF TAMOXIFEN IN CYCLIC AND NON-CYCLIC MASTALGIA
SERDAR SAYDAM, SEYMEN BORA, METİN KARAASLAN, ÖMER HARMANCIOĞLU, HASAN BAKIR, KEMAL ASTARCIOĞLU
Dokuz Eylül Üniversitesi Tıp Fakültesi, Genel Cerrahi ABD, İnciraltı, İZMİR
For evaluating the effects of tamoxifen in patients with severe cyclic and non-cyclic mastalgia of more than 6 months' duration, the drug was given 10 mgr/daily for 3 months and compared with the placebo. In the cyclic mastalgia group pain relief was achieved in 13/19 (%68) of those receiving tamoxifen and 6/12 (%50) of those taking placebo. In the non-cyclic mastalgia group, pain relief was achieved in 17/20 (%85) of those receiving tamoxifen and 9/16 (%56) of those taking placebo. The success rate of treatment was not significant in the cyclic and non-cyclic mastalgia between tamoxifen and plasebo (p>0.01). These results suggest that tamoxifen should not be preferred as a first drug of choice in the treatment of mastalgia.